Invivyd (IVVD) EBITDA (2021 - 2025)
Invivyd (IVVD) posted EBITDA of -$12.6 million for Q4 2025, down 13.9% on a QoQ basis from -$11.0 million in Q3 2025, and up 34.71% year-over-year from -$9.3 million in Q4 2024.
Invivyd (IVVD) EBITDA (2021 - 2025) Analysis & Trends
Invivyd's EBITDA history runs 5 years deep, the most recent figure standing at -$12.6 million for Q4 2025.
- Quarterly EBITDA rose 34.71% year-over-year to -$12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$55.6 million (up 68.59% YoY) and the FY2025 annual result came in at -$55.6 million, up 68.59% from the prior year.
- EBITDA was -$12.6 million for Q4 2025 at Invivyd, down from -$11.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$11.0 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
- A 5-year average of -$46.0 million and a median of -$46.7 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 160.25% — and 2025, when it soared 82.31%.
- Invivyd's EBITDA stood at -$83.1 million in 2021, then surged by 41.98% to -$48.2 million in 2022, then sank by 59.2% to -$76.8 million in 2023, then surged by 74.95% to -$19.2 million in 2024, then surged by 34.71% to -$12.6 million in 2025.
- Business Quant data shows IVVD's EBITDA at -$12.6 million in Q4 2025, -$11.0 million in Q3 2025, and -$15.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Invivyd | 103.48 Mn | -123.21 Mn | 16.07 Mn | -12.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.42 Mn |
| Jun 30, 2021 | -44.69 Mn |
| Mar 31, 2021 | -38.71 Mn |